v3.26.1
Equity-Based Compensation - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Aug. 20, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Recognized stock-based compensation expense $ 16,007 $ 14,234  
Equity-based compensation expense 16,007 14,234  
Research and Development Expense      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Recognized stock-based compensation expense 8,580 7,546  
Equity-based compensation expense 8,580 7,546  
General and Administrative      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Recognized stock-based compensation expense 7,427 6,688  
Equity-based compensation expense 7,427 6,688  
Employee Stock Option      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Intrinsic value of stock options exercised $ 33,300 $ 2,100  
Weighted-average fair value of options granted $ 62.98 $ 20.66  
Recognized stock-based compensation expense $ 12,005 $ 11,570  
Unrecognized stock-based compensation expense $ 116,200    
Unrecognized compensation cost, recognition period 3 years 9 months 18 days    
Equity-based compensation expense $ 12,005 11,570  
Employee Stock Option | Research and Development Expense      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Recognized stock-based compensation expense 5,717 5,713  
Equity-based compensation expense 5,717 5,713  
Employee Stock Option | General and Administrative      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Recognized stock-based compensation expense 6,288 5,857  
Equity-based compensation expense 6,288 5,857  
Restricted Stock      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Recognized stock-based compensation expense $ 3,800 $ 2,400  
Unrecognized compensation cost, recognition period 3 years 2 months 12 days    
Granted 344,242 327,800  
Unrecognized stock-based compensation expense $ 54,100    
Equity-based compensation expense 3,800 $ 2,400  
Restricted Stock | Research and Development Expense      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Recognized stock-based compensation expense 2,700 1,600  
Equity-based compensation expense 2,700 1,600  
Restricted Stock | General and Administrative      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Recognized stock-based compensation expense 1,100 800  
Equity-based compensation expense $ 1,100 800  
2020 Plan      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Number of shares authorized for issuance under plan     4,457,370
Maximum number of shares to be issued, percentage 4.00%    
Shares remaining available for future grants 6,667,087    
Weighted-average fair value of options granted $ 97.53    
Recognized stock-based compensation expense $ 100 $ 0  
Performance stock options vesting 60.00% 40.00%  
Second clinical milestone vesting percentage   40.00%  
Third clinical milestone vesting percentage 15.00% 20.00%  
Granted 95,000 88,000  
Option Indexed to Issuer's Equity, Strike Price   $ 30.17  
Performance stock options outstanding 88,000    
Equity-based compensation expense $ 100 $ 0  
2020 Plan | Restricted Stock      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Unrecognized compensation cost, recognition period 2 years 9 months 18 days    
Granted 73,672 285,723  
Unrecognized stock-based compensation expense $ 2,300    
2020 Plan | Performance Stock      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Weighted-average fair value of options granted $ 126.09    
Recognized stock-based compensation expense $ 100    
Performance stock options vesting 60.00% 40.00%  
Second clinical milestone vesting percentage   40.00%  
Third clinical milestone vesting percentage 15.00% 20.00%  
Granted   285,723  
Option Indexed to Issuer's Equity, Strike Price $ 30.17    
Equity-based compensation expense $ 100    
2020 Plan | Minimum [Member]      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Performance stock options range 0.00% 0.00%  
2020 Plan | Minimum [Member] | Performance Stock      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Performance stock options range 0.00% 0.00%  
2020 Plan | Maximum [Member]      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Performance stock options range 100.00% 100.00%  
2020 Plan | Maximum [Member] | Performance Stock      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Performance stock options range 100.00% 100.00%  
2020 ESPP      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Number of shares authorized for issuance under plan     445,653
Shares remaining available for future grants 2,742,310    
Share-based compensation, description The 2020 ESPP provides that the number of shares reserved and available for issuance will automatically increase on January 1, 2021 and each January 1 thereafter through January 1, 2030, by the lesser of (i) 438,898 shares of common stock, (ii) 1% of the Company’s outstanding number of shares of common stock on the immediately preceding December 31 or (iii) such lesser number of shares of common stock as determined by the administrator of the 2020 ESPP.    
2020 ESPP | Lesser of Potential Outcome 1      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Maximum number of shares to be issued, percentage 1.00%    
Number of additional shares authorized 438,898    
2018 Plan | Restricted Stock      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Granted 417,914